Luo Chang, Deng Ying-Ping
Department of Ophthalmology, West China Hospital, Sichuan University, 37# Guo Xue Xiang, Chengdu 610041, Sichuan Province, China.
Int J Ophthalmol. 2013 Jun 18;6(3):397-401. doi: 10.3980/j.issn.2222-3959.2013.03.26. Print 2013.
Retinoblastoma (RB) is the most common intraocular cancer of infancy and childhood. This cancer is initiated by mutation on RB1, the tumor suppressor gene that is responsible for the regulation of both cell cycle and gnome stability in retinal cells. Patients with a constitutional mutation on RB1 can be inherited. RB occurs approximately 1 in every 15 000-20 000 live births. The worldwide mortality for this cancer is about 5%-11%. However, this rate rises to about 40%-70% in developing countries due to a delay in diagnosis. A wide variety of options are available for the treatment, but often a combination of therapies is adopted to optimize individualized care.
视网膜母细胞瘤（RB）是婴幼儿及儿童时期最常见的眼内癌。这种癌症由RB1基因突变引发，RB1是一种肿瘤抑制基因，负责调节视网膜细胞的细胞周期和基因组稳定性。携带RB1基因体质性突变的患者可能会遗传该疾病。RB的发病率约为每15000 - 20000例活产中有1例。这种癌症的全球死亡率约为5% - 11%。然而，由于诊断延误，在发展中国家这一比例会升至约40% - 70%。治疗有多种选择，但通常会采用联合疗法以优化个性化护理。
